210 related articles for article (PubMed ID: 29355722)
1. Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report.
Mulder P; de Korte T; Dragicevic E; Kraushaar U; Printemps R; Vlaming MLH; Braam SR; Valentin JP
J Pharmacol Toxicol Methods; 2018; 91():36-42. PubMed ID: 29355722
[TBL] [Abstract][Full Text] [Related]
2. The assessment of electrophysiological activity in human-induced pluripotent stem cell-derived cardiomyocytes exposed to dimethyl sulfoxide and ethanol by manual patch clamp and multi-electrode array system.
Hyun SW; Kim BR; Hyun SA; Seo JW
J Pharmacol Toxicol Methods; 2017 Sep; 87():93-98. PubMed ID: 28377112
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
[TBL] [Abstract][Full Text] [Related]
4. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
Goineau S; Castagné V
J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
[TBL] [Abstract][Full Text] [Related]
5. Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes.
Jans D; Callewaert G; Krylychkina O; Hoffman L; Gullo F; Prodanov D; Braeken D
J Pharmacol Toxicol Methods; 2017 Sep; 87():48-52. PubMed ID: 28549786
[TBL] [Abstract][Full Text] [Related]
6. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
[TBL] [Abstract][Full Text] [Related]
7. The effects of gentamicin and penicillin/streptomycin on the electrophysiology of human induced pluripotent stem cell-derived cardiomyocytes in manual patch clamp and multi-electrode array system.
Hyun SW; Kim BR; Lin D; Hyun SA; Yoon SS; Seo JW
J Pharmacol Toxicol Methods; 2018; 91():1-6. PubMed ID: 29288713
[TBL] [Abstract][Full Text] [Related]
8. Interpretation of field potentials measured on a multi electrode array in pharmacological toxicity screening on primary and human pluripotent stem cell-derived cardiomyocytes.
Tertoolen LGJ; Braam SR; van Meer BJ; Passier R; Mummery CL
Biochem Biophys Res Commun; 2018 Mar; 497(4):1135-1141. PubMed ID: 28153730
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
[TBL] [Abstract][Full Text] [Related]
10. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
Satsuka A; Kanda Y
Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of in vitro models of stem cell-derived cardiomyocytes to screen for potential cardiotoxicity of chemicals.
Shi M; Tien NT; de Haan L; Louisse J; Rietjens IMCM; Bouwmeester H
Toxicol In Vitro; 2020 Sep; 67():104891. PubMed ID: 32446838
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity screening of illicit drugs and new psychoactive substances (NPS) in human iPSC-derived cardiomyocytes using microelectrode array (MEA) recordings.
Zwartsen A; de Korte T; Nacken P; de Lange DW; Westerink RHS; Hondebrink L
J Mol Cell Cardiol; 2019 Nov; 136():102-112. PubMed ID: 31526813
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi).
Takasuna K; Kazusa K; Hayakawa T
Curr Pharm Biotechnol; 2020; 21(9):829-841. PubMed ID: 31749424
[TBL] [Abstract][Full Text] [Related]
16. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
[TBL] [Abstract][Full Text] [Related]
17. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
18. A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes.
Ando H; Yoshinaga T; Yamamoto W; Asakura K; Uda T; Taniguchi T; Ojima A; Shinkyo R; Kikuchi K; Osada T; Hayashi S; Kasai C; Miyamoto N; Tashibu H; Yamazaki D; Sugiyama A; Kanda Y; Sawada K; Sekino Y
J Pharmacol Toxicol Methods; 2017; 84():111-127. PubMed ID: 27956204
[TBL] [Abstract][Full Text] [Related]
19. Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system.
Kanda Y; Yamazaki D; Kurokawa J; Inutsuka T; Sekino Y
J Pharmacol Toxicol Methods; 2016; 81():196-200. PubMed ID: 27369811
[TBL] [Abstract][Full Text] [Related]
20. Impact of calcium-sensitive dyes on the beating properties and pharmacological responses of human iPS-derived cardiomyocytes using the calcium transient assay.
Kopljar I; Hermans AN; Teisman A; Gallacher DJ; Lu HR
J Pharmacol Toxicol Methods; 2018; 91():80-86. PubMed ID: 29421525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
